Symbols

Symbols

Aime

Products

News

Markets

Watchlist

Brokers

News/

Stock/

LCTX

LCTX News

Newswire

16:54

Lineage Cell Therapeutics Maintains Buy Recommendation by D. Boral Capital; Analyst Price Forecast Suggests 142.86% Upside

08:03

Lineage Cell: D. Boral Capital raises PT to $2, maintains Buy rating.

04:12

Lineage Cell Therapeutics: A Viable Speculative Buy for Regenerative Medicine

22:09

Lineage Cell Therapeutics Extends Cash Runway into Q2 2027 with OpRegen Expansion and New Partnerships

16:19

Lineage Cell Therapeutics Q3 revenue up 34% YoY to $5.6 mln.

View More

About LCTX

Charts

--

Sector--

Established Date--

Listing Date--

Exchange--

Full-time Employees--

Fiscal Year Ends--

Website

Security Type--

Office address

Business

Introduction

View More